IMUX - Three Biotech Innovators: iBio, Nektar, and Immunic Poised for Market-Moving News

2025-06-24 07:19:56 ET

DENVER, Colo., Jun 24, 2025 ( 247marketnews.com )- Three biotech companies, iBio (NASDAQ:IBIO) , Nektar Therapeutics (NASDAQ:NKTR) , and Immunic (NASDAQ:IMUX) , are stepping into the spotlight this week with pivotal updates. From next-generation obesity therapeutics to novel immune modulators and long-term multiple sclerosis data, these companies are delivering the kind of catalysts that often precede sharp market moves.

iBio (IBIO): Expanding the Obesity Pipeline and AstralBio Collaboration

iBio is hosting a major conference call today at 8:30 a.m. ET to unveil its latest preclinical data in obesity and cardiometabolic disease , two of the most high-demand therapeutic areas in biotech today. The company will also announce the third target in its collaboration with AstralBio , joining Myostatin and Activin E.

Led by CEO and CSO Dr. Martin Brenner , iBio is emphasizing next-generation antibody therapeutics, longer-acting, more tolerable , and potentially more durable than current standard-of-care agents. The pipeline includes IBIO-600 , a long-acting Myostatin antibody designed to improve lean body mass and metabolic health, and new data on its Activin E program , aimed at regulating energy expenditure.

Dr. Brenner will present “a strategic overview of the obesity strategy,” focusing on how iBio’s AI-powered platform is enabling more precise, patient-tailored antibody designs.

With obesity and cardiometabolic disease representing a multi-billion-dollar market , even preclinical data can have a meaningful impact, particularly as iBio expands its pipeline and attracts potential partnerships.

Nektar Therapeutics (NKTR): Phase 2b Data for Atopic Dermatitis Drug Could Be Pivotal

Nektar will also be in the headlines on June 24 today at 8:15 a.m. ET , when it reports top-line data from the 16-week induction period of its REZOLVE-AD Phase 2b trial for rezpegaldesleukin , a regulatory T-cell (Treg) proliferator being developed for moderate-to-severe atopic dermatitis (AD).

This is a key inflection point for Nektar. Positive results could validate the novel mechanism of expanding Tregs to calm overactive immune responses , a strategy applicable not only to AD but potentially to a broad range of autoimmune diseases .

The company will release a press release with results Tuesday morning , followed by an investor call and webcast. Nektar is under close watch from institutional investors after recent restructuring and data from other immunology assets failed to meet expectations. The REZOLVE-AD data represents a chance to rebuild confidence and potentially re-rate the stock if efficacy and safety signals align.

Immunic (IMUX): Long-Term MS Data Supports Durability and Safety of Vidofludimus Calcium

Immunic recently announced new long-term open-label extension data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in patients with relapsing-remitting multiple sclerosis (RRMS) . The numbers are impressive:

• At week 144 , 92.3% of patients remained free of 12-week confirmed disability worsening (CDW)
• 92.7% remained free of 24-week CDW
• Safety remains consistent, with no new safety signals emerging even after up to 5.5 years of treatment

The durability data reinforces vidofludimus calcium’s potential as a long-term, oral therapy with disease-modifying benefits . It’s also noteworthy that low discontinuation rates and minimal serious adverse events reflect a favorable tolerability profile—a key differentiator in a crowded MS space.

With over 950 patient-treatment years now documented, the company is building a strong case as it gears up for phase 3 development or potential licensing discussions .

As the biotech sector continues to rotate into high-conviction innovation stories, these three names are worth watching closely. A strong showing from any of them could ignite not just upside in their respective stocks, but renewed interest across the small-cap biotech space more broadly.

The post Three Biotech Innovators: iBio, Nektar, and Immunic Poised for Market-Moving News appeared first on 24/7 MarketNews .

For further details see: